After weight loss regular exercise rather than GLP-1 weight-loss drug reduces leading cause of heart attack and strokes
Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity—a leading underlying cause of cardiovascular disease.
The study of adults with obesity but not diabetes is by researchers from the University of Copenhagen, Denmark, and is presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna ...